Indivior (NASDAQ:INDV) Experiences Significant Trading Volume – Is It Time to Invest?

Indivior PLC (NASDAQ:INDV) experienced a notable surge in trading volume on Friday. During mid-day trading, approximately 419,314 shares were exchanged, reflecting a 6% increase compared to the previous day's volume of 396,994 shares. The stock was last quoted at $7.58, having previously closed at $7.98.

Wall Street Recommendations Predict Future Growth

The stock has sparked interest among analysts, leading to various research reports regarding its future performance. In a recent report from Craig Hallum, the price target for Indivior was adjusted downward from $20.00 to $16.00, while maintaining a "buy" rating for the stock. Similarly, Piper Sandler reaffirmed an "overweight" rating, revising the target price from $22.00 down to $15.00.

Indivior's Stock Performance Metrics

The company exhibits a debt-to-equity ratio of 23.50, a quick ratio of 0.68, and a current ratio of 0.85. With a market capitalization of approximately $1.02 billion, its price-to-earnings (P/E) ratio stands at 759.00 and its beta is measured at 0.68. The stock's 50-day moving average is $11.11, while the 200-day moving average is $14.80.

Indivior last reported its quarterly earnings on July 25th, where it posted $0.44 earnings per share (EPS), exceeding the consensus estimate of $0.40 by $0.04. The company faced a negative net margin of 12.29% and a staggering negative return on equity of 654.82%. The total revenue for the quarter reached $299.00 million, which surpassed the estimated revenue of $285.90 million. Analysts predict that Indivior PLC will report an average of 1.7 EPS for the current fiscal year.

Institutional Investment Trends

Recent movements by institutional investors indicate a growing interest in Indivior. M&G Plc established a new position in the company during the first quarter, acquiring approximately $2,518,000 worth of shares. Janus Henderson Group PLC increased its stake by 14.2%, now holding 440,121 shares valued at $9,424,000 after adding another 54,750 shares in the last quarter. Additionally, Vanguard Group Inc. boosted its position by 0.9% during the fourth quarter, resulting in ownership of 5,899,190 shares worth $90,081,000, post an acquisition of 52,836 new shares. Quadrature Capital Ltd. also purchased new shares valued at approximately $1,523,000 during the first quarter, followed by Susquehanna International Group Ltd., which acquired shares worth $3,224,000 in the second quarter. Currently, institutional investors and hedge funds hold about 60.33% of the company's equity.

About Indivior PLC

Indivior PLC, along with its subsidiaries, specializes in developing, manufacturing, and selling buprenorphine-based prescription medications aimed at treating opioid dependence and associated disorders in the United States, United Kingdom, and globally. The company is committed to creating medications for addressing substance use disorders, serious mental health issues, and opioid overdoses.

Final Thoughts on Investing in Indivior

Considering the recent developments and trading activity surrounding Indivior, potential investors may be assessing whether to buy shares. While analysts maintain a general "buy" sentiment for Indivior, it is essential to review other recommendations and stock analyses.

Investors should keep in mind that while Indivior shows promise, there are numerous other stocks that analysts believe could present more favorable investment opportunities. For those contemplating whether to invest $1,000 in Indivior right now, it may be wise to further investigate other suggestions from top-rated research analysts.

Indivior, Trading, Stocks